Skip to main content
Top
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Melanoma | Hypothesis

ROR2, a driver of “phenotype switching” in melanoma?

Author: Pablo Lopez-Bergami

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a receptor for the Wnt5a ligand that was shown to play a dual role in cancer. ROR2 was shown to either suppress or promote tumor progression in different tumor types by regulating the same biological processes (i.e. proliferation, invasion) in opposite ways. We have recently observed that ROR2 plays multiple and somewhat contradictory roles in melanoma where it impairs cell proliferation but promotes migration, EMT and chemoresistance. In the present article, ROR2 is proposed to be a major driver of “phenotype switching” in melanoma that can tilt the cellular behavior toward proliferative or invasive phenotypes. This function of ROR2 has therapeutic implications since it would provide an opportunity for targeting specific phenotypes such as invasive and drug-resistant ones by inhibiting ROR2.
Literature
1.
go back to reference Ford CE, Qian Ma SS, Quadir A, Ward RL. The dual role of the novel wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer. 2013;133:779–87.CrossRef Ford CE, Qian Ma SS, Quadir A, Ward RL. The dual role of the novel wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer. 2013;133:779–87.CrossRef
2.
go back to reference Castro MV, Lopez-Bergami P. Cellular and molecular mechanisms implicated in the dual role of ROR2 in cancer. Crit Rev Oncol Hematol. 2022;170: 103595.CrossRef Castro MV, Lopez-Bergami P. Cellular and molecular mechanisms implicated in the dual role of ROR2 in cancer. Crit Rev Oncol Hematol. 2022;170: 103595.CrossRef
3.
go back to reference Castro MV, Barbero GA, Villanueva MB, Grumolato L, Nsengimana J, Newton-Bishop J, et al. ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation. J Biomed Sci. 2021;28:76.CrossRef Castro MV, Barbero GA, Villanueva MB, Grumolato L, Nsengimana J, Newton-Bishop J, et al. ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation. J Biomed Sci. 2021;28:76.CrossRef
4.
go back to reference Castro MV, Barbero GA, Máscolo P, Ramos R, Quezada MJ, Lopez-Bergami P. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation. Cell Mol Biol Lett. 2022;27:23.CrossRef Castro MV, Barbero GA, Máscolo P, Ramos R, Quezada MJ, Lopez-Bergami P. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation. Cell Mol Biol Lett. 2022;27:23.CrossRef
6.
go back to reference Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 2010;23:746–59.CrossRef Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 2010;23:746–59.CrossRef
7.
go back to reference Ghislin S, Deshayes F, Middendorp S, Boggetto N, Alcaide-Loridan C. PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle. 2012;11:1634–45.CrossRef Ghislin S, Deshayes F, Middendorp S, Boggetto N, Alcaide-Loridan C. PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle. 2012;11:1634–45.CrossRef
8.
go back to reference Fane ME, Chhabra Y, Smith AG, Sturm RA. BRN2, a POUerful driver of melanoma phenotype switching and metastasis. Pigment Cell Melanoma Res. 2019;32:9–24.CrossRef Fane ME, Chhabra Y, Smith AG, Sturm RA. BRN2, a POUerful driver of melanoma phenotype switching and metastasis. Pigment Cell Melanoma Res. 2019;32:9–24.CrossRef
9.
go back to reference Janssen SM, Moscona R, Elchebly M, Papadakis AI, Redpath M, Wang H, et al. BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells. Cell Death Discov. 2020;6:1.CrossRef Janssen SM, Moscona R, Elchebly M, Papadakis AI, Redpath M, Wang H, et al. BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells. Cell Death Discov. 2020;6:1.CrossRef
10.
go back to reference O’Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et al. Hypoxia Induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013;3:1378–93.CrossRef O’Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et al. Hypoxia Induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013;3:1378–93.CrossRef
11.
go back to reference Dissanayake SK, Wade M, Johnson CE, O’Connell MP, Leotlela PD, French AD, et al. The Wnt5A/protein kinase c pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282:17259–71.CrossRef Dissanayake SK, Wade M, Johnson CE, O’Connell MP, Leotlela PD, French AD, et al. The Wnt5A/protein kinase c pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282:17259–71.CrossRef
12.
go back to reference Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Investig. 2014;124:2877–90.CrossRef Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Investig. 2014;124:2877–90.CrossRef
13.
go back to reference Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, et al. Understanding molecular mechanisms of phenotype switching and crosstalk with tme to reveal new vulnerabilities of melanoma. Cells. 2022;11:1157.CrossRef Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, et al. Understanding molecular mechanisms of phenotype switching and crosstalk with tme to reveal new vulnerabilities of melanoma. Cells. 2022;11:1157.CrossRef
14.
go back to reference Xu J, Shi J, Tang W, Jiang P, Guo M, Zhang B, et al. ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK/p38 signaling pathway in breast cancer. J Cell Biochem. 2020;121(10):4142–53.CrossRef Xu J, Shi J, Tang W, Jiang P, Guo M, Zhang B, et al. ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK/p38 signaling pathway in breast cancer. J Cell Biochem. 2020;121(10):4142–53.CrossRef
15.
go back to reference Tang Y, Durand S, Dalle S, Caramel J. EMT-inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment. Cancers. 2020;12:2154.CrossRef Tang Y, Durand S, Dalle S, Caramel J. EMT-inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment. Cancers. 2020;12:2154.CrossRef
16.
go back to reference O’Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29:34–44.CrossRef O’Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29:34–44.CrossRef
17.
go back to reference Tseng H-C, Lyu P-C, Lin W. Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain. BMC Cell Biol. 2010;11:48.CrossRef Tseng H-C, Lyu P-C, Lin W. Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain. BMC Cell Biol. 2010;11:48.CrossRef
18.
go back to reference Chen M-K, Hung M-C. Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS J. 2015;282:3693–721.CrossRef Chen M-K, Hung M-C. Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS J. 2015;282:3693–721.CrossRef
19.
go back to reference Tseng H-C, Kao H-W, Ho M-R, Chen Y-R, Lin T-W, Lyu P-C, et al. Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. Anticancer Res. 2011;31:4239–49.PubMed Tseng H-C, Kao H-W, Ho M-R, Chen Y-R, Lin T-W, Lyu P-C, et al. Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. Anticancer Res. 2011;31:4239–49.PubMed
20.
go back to reference Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.CrossRef Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.CrossRef
22.
go back to reference Du B, Shim J. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21:965.CrossRef Du B, Shim J. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21:965.CrossRef
23.
go back to reference Huang F, Santinon F, Flores González RE, del Rincón SV. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front Oncol. 2021;11: 756001.CrossRef Huang F, Santinon F, Flores González RE, del Rincón SV. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front Oncol. 2021;11: 756001.CrossRef
Metadata
Title
ROR2, a driver of “phenotype switching” in melanoma?
Author
Pablo Lopez-Bergami
Publication date
01-12-2022
Publisher
BioMed Central
Keywords
Melanoma
Melanoma
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02711-x

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine